The role of the hospice medical director is critical for programmatic success and good patient care. To this end, the report by Debra Parker-Oliver 1 adds important new information on this function, including practice patterns. In brief, she surveyed 84 hospice medical and program directors regarding demographics and pain management practices of these physicians in a Midwestern state. The results of pain management practice were then compared to national standards as they exist in the medical literature. Several observations are in order.
First, most hospice medical directors were experienced practicing physicians. One-third were family physicians, one-third were oncologists, one-quarter were internal medicine specialists and the remaining were of varied specialties. The majority of the hospice medical directors had been in hospice programs less than five years and one-fifth less than one year. The average time involved in hospice care was between six and 10 hours monthly. More than one-half of these physicians reported no training in hospice care and support for continuing education was generally not available. Although publications regarding the demographics of hospice medical directors are scant, McCann and Enck reported the results of a JCAHO survey of more than 200 hospices in the early days of hospice in 1982. 2 At that time, the vast majority of hospice medical directors were oncologists, followed by family physicians and internal medicine specialists. Of interest, there was a relationship between the employment status and compliance with the hospice standards. Programs with a full-or part-time medical director had a much higher level of standard compliance in comparison with a committee of physicians or volunteer physicians. The implication of this survey was clear: better care was given in those programs with more medical director involvement. Although the studies by Parker-Oliver 1 and McCann and Enck 2 are years apart, the increasing role of family physicians as hospice medical directors is obvious. This, in part, may reflect the growing numbers of noncancer patients accessing hospice care or less interest on the part of oncologists in serving as medical directors. Utilization of the medical director for only six to 10 hours monthly is quite bothersome and may reflect, in some circumstances, the titular function of the physician to satisfy regulatory requirements. Again, as noted by McCann and Enck, 2 there was a positive correlation between the amount of time the medical director participated in hospice and quality of care.
Although training and continuing education were minimal for the medical directors surveyed by Parker-Oliver, 1 they performed quite admirably in comparison to accepted standards of practice as reported in the medical literature. This addresses the second point, that is, what is the national standard of practice for pain management? The Agency for Heath Care Policy and Research (AHCPR) published guidelines for cancer pain management in 1994. This report, like others, represents a consensus of opinion, a subject that has been so eloquently reviewed by Sniderman in a recent issue of Lancet. 3 practice. These conferences, as he writes, are often as much a social as a scientific process with participants advocating their particular views. This social nature may lead to imperfect scientific recommendations. Furthermore, he recommends timely revisions of guidelines in response to advances in knowledge and technology. Finally, Sniderman warns: "We clinicians cannot become so weary that we abandon the responsibility of thinking for ourselves."
The AHCPR guidelines have not been revised in five years. Technology trudges forward along with differences of opinion. For example, transdermal fentanyl has enjoyed widespread use, especially in patients with stable baseline pain. Payne et al. 4 recently reported the results of a quality-of-life study comparing transdermal fentanyl (Duragesic) to sustainedrelease oral forms of morphine sulfate (MS Contin or Oramorph SR). The majority of the 504 patients in both treatment groups had advanced cancer. Patients who were given transdermal fentanyl were more satisfied overall with their pain medication than those who received sustained-release oral morphine. The fentanyl patients experienced a significantly lower frequency and impact of side effects due to the pain medication. In addition, these findings occurred despite the fact that the fentanyl patients were significantly older, lower functioning, and had lower well-being scores. The authors concluded that fewer side effects might be one reason that cancer patients treated with transdermal fentanyl were more satisfied with their pain management. These findings certainly differ from the literature cited by Parker-Oliver, 1 again reflecting divergent opinions on the use of transdermal fentanyl.
Another example is the amount of "rescue" opioid dosing for breakthrough pain. The American Pain Society (APS), as cited by Parker-Oliver, 1 recommends 25 to 30 percent of the 12-hour baseline dosage as the "rescue" dose. However, Abrahm, 5 writing for the American College of Physicians (ACP)-American Society of Internal Medicine (ASIM) End-of-Life Consensus Panel, suggests that this dose should be 10 percent of the 24-hour opioid dosage. If the APS standard is converted to a 24-hour "rescue" dosing percentage, there is a fivefold difference between the APS and ACP-ASIM recommendations! So, what is the national standard? These two examples merely reflect the difficult, often impossible, task of setting national pain management standards. Perhaps, Louis Pasteur said it best: "There are no such things as applied sciences, only applications of science."
Finally, these comments are not to detract from, but rather to enhance, the study by Parker-Oliver 1 with its important conclusion that more training and support, specifically financial support, for physicians' continuing education be available to hospice medical directors. Amen!
